Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center, randomized phase II study comparing the Y90 TARE
followed by bevacizumab and atezolizumab treatment to the Y90 TARE treatment alone in
unresectable intermediate stage HCC.